TY  - JOUR
AU  - Aomar-Millán, Ismael Francisco
AU  - Salvatierra, Juan
AU  - Torres-Parejo, Úrsula
AU  - Faro-Miguez, Naya
AU  - Callejas-Rubio, José Luis
AU  - Ceballos-Torres, Ángel
AU  - Cruces-Moreno, María Teresa
AU  - Gómez-Jiménez, Francisco Javier
AU  - Hernández-Quero, José
AU  - Anguita-Santos, Francisco
PY  - 2021
DO  - 10.1007/s11739-020-02600-z
UR  - http://hdl.handle.net/10668/16921
T2  - Internal and emergency medicine
AB  - Little evidence appears to exist for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate...
LA  - en
KW  - Anakinra
KW  - COVID-19
KW  - Cytokine storm syndrome
KW  - Hyperinflammation
KW  - Methylprednisolone
KW  - Tocilizumab
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Antirheumatic Agents
KW  - COVID-19
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glucocorticoids
KW  - Humans
KW  - Interleukin 1 Receptor Antagonist Protein
KW  - Male
KW  - Methylprednisolone
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Spain
KW  - Survival Rate
KW  - Treatment Outcome
KW  - COVID-19 Drug Treatment
TI  - Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
TY  - research article
VL  - 16
ER  -